Britanci ce biti odusevljeni a ionako ih Kinezi kupuju
Apple to design power chips in-house as early as 2018: Sources Nikkei staff writers Debby Wu and Kensaku Ihara in Taipei contributed to this report. Current developer UK's Dialog Semiconductor could be hit
TAIPEI -- Apple is designing its own main power management chips for use in iPhones as early as in 2018, cutting dependence on Dialog Semiconductor, according to industry sources, as it seeks to boost its semiconductor capabilities to better compete with rivals. The main power management chip controls an iPhone's charging function, battery management, and energy consumption. "Based on Apple's current plan, they are set to replace partially, or around half of its power management chips to go into iPhones by itself starting next year," said the source. Another person said Apple was indeed developing its own power management chips for iPhones but the time frame was less certain and could be delayed to 2019. Apple's main power management chips for the iPhone, iPad and Apple Watch are now exclusively designed by U.K.-based Dialog Semiconductor, according to Credit Suisse. Apple accounted for 74% of Dialog's revenue in 2016. Power management chips are one of the most crucial and expensive components after core processors, modems and memory chips. Apple is keen to boost production of its own semiconductors to better compete in emerging technologies such as artificial intelligence applications and reduce reliance on external chip designers. By developing more of its own chips, Apple will also be in a better position to integrate software and hardware and to manufacture products that can be differentiated from those of its rivals such as Samsung Electronics and Huawei Technologies, according to analysts. Apple's new in-house power management chip would be the most advanced in the industry, according to the sources, and could have processing capabilities that allow it to better monitor and control power consumption among various components. That means iPhone users could expect devices capable of delivering better performance on lower power consumption. Such new chips will be solely manufactured by Taiwan Semiconductor Manufacturing Co., the world's largest contract chipmaker, according to the industry sources. TSMC has been Apple's sole supplier manufacturing core processor chips for iPhones since 2016. Currently Dialog's power management chips for Apple's iPhones are also made by TSMC. In 2016, Apple was TSMC's No.1 customer, contributing 17% to the Taiwanese chipmaker's overall revenue. That contribution will grow to around 20% in 2017 and continue to rise in 2018, according to Bernstein Research. The U.S. tech giant already designs its own core processors, a bionic neural engine chip to handle facial, image and speech recognition and other machine-learning algorithms. It also builds its own fingerprint chips, and a connection chip used in Airpods to allow seamless pairing with other Apple products with the wireless headphone.
Apple is also building its own graphic processor and will no longer use ones provided by Imagination Technologies in 15 months to two years' time, the British chip designer said in a statement in April. That decision crushed Imagination as Apple was its no.1 customer that accounted for over half of its revenue. The British chip designer eventually sold itself to Canyon Bridge, a private equity investment fund backed by state-owned Chinese fund Yitai Capital, in September. Dialog Semiconductor shares in Frankurt closed down 16% on April 11, following a note from private bank Bankhaus Lampe suggesting that Apple could cut back the use of the company's power management integrated circuits. Dialog declined to comment directly on Apple's move but said in a statement: "Business relationships are in line with the normal course of business." TSMC's Spokeswoman Elizabeth Sun declined to comment on any particular customer's business, citing company policy. Apple did not respond to requests for comment.
Germany removes Tesla from subsidies list as too pricey https://www.reuters.com/article/us-tesla-subsidies-germany/germany-removes-tesla-from-subsidies-list-as-too-pricey-idUSKBN1DV4SB
E.U. and Japan Reach Deal to Keep ‘Flag of Free Trade Waving High’ The deal is subject to ratification by lawmakers in Europe as well as Japan, but Mr. Abe and Mr. Juncker said that they were confident that once in place, it would “deliver sustainable and inclusive economic growth, and spur job creation.”
O ovakvom namernom usporavanju uređaja se piše već godinama, međutim ni jedan proizvođač do sada nije javno priznao da se uređaji namerno usporavaju kroz nadogradnje softvera.
Navodno se uređaji usporavaju zbog slabljenja kapaciteta baterija, a sve u cilju izbegavanja oštećenja na uređajima. Apple je kroz nadogradnju softvera prošle godine aktivirao opciju na modelima iPhone 6, 6S i iPhone SE, dok je na modelu iPhone 7 ova opcija aktivirana u decembarskoj nadogradnji na iOS 11.2. Ova opcija će takođe biti aktivirana i na ovogodišnjim modelima u budućnosti.
A Message to Our Customers about iPhone Batteries and Performance We’ve been hearing feedback from our customers about the way we handle performance for iPhones with older batteries and how we have communicated that process. We know that some of you feel Apple has let you down. We apologize. There’s been a lot of misunderstanding about this issue, so we would like to clarify and let you know about some changes we’re making. First and foremost, we have never — and would never — do anything to intentionally shorten the life of any Apple product, or degrade the user experience to drive customer upgrades. Our goal has always been to create products that our customers love, and making iPhones last as long as possible is an important part of that.
Lek za lecenje jedne vrste slepila kroz genetsku terapiju izbacen na trziste, cijena prava sitnica...
Luxturna gene therapy for blindness to cost $850,000
Luxturna was just approved by the Food and Drug Administration last month after a dramatic hearing where teenagers spoke of seeing the stars in the night sky for the first time in years and at which eye doctors with no links to the company or the drug pleaded for its approval. It’s the first true gene therapy approved in the U.S. for an inherited genetic disease — vision loss caused by mutations in a gene called RPE65. It’s very rare, affecting only a few thousand people in the U.S.
The mutation causes the gradual disruption of the cells located in the back of the eye that form the retina. Patients gradually lose their vision and go blind. There’s no cure now. The treatment involves injecting a modified cold virus — one called an adeno-associated virus — directly into the eye to deliver corrected genes to the retina. Surprisingly, a single treatment helped most of the 21 volunteers who got it, reversing vision loss almost immediately.
It’s the first true gene therapy approved in the U.S. for an inherited genetic disease
i uhvatis se za cenu leka koja je formirana na osnovu 1) cinjenice da su u razvoj ulozene grdne pare i 2) da celokupna globalna potreba za ovim lekom staje u gepek Punta. Mi sada placamo novcicima lekove koji su u vreme pojavljivanja kostali kao svetog Petra kajgana. Jednostavno ciklus je takav, ima svoje faze i uvek se zavrsava time da lek postaje genericki i ne kosta prakticno nista u proizvodnji.
Zuper wrote:Preduzetnicki duh Henrija Forda lezi u nasem kolegi
Ne nego postoji mehanizam zahvaljujuci kome ljudi sada, na primer, Sortis placaju oko 2.000 dinara, a za paracetamol istresaju sitninu iz dzepa. Cene u Americi su njihov problem i anomalija koju sami treba da rese, ali to se svakako ne odnosi na eksperimentalni lek sa izuzetno ogranicenom primenom ali sa ogromnim implikacijama za medicinu i farmakopeju.
Drugi deo ne znam kako da razumem, bukvalno nista ne ukazuje na takav trend, u zemljama nekadasnjeg Treceg sveta sada buja genericka farmaceutska industrija.
I ja bih zeleo da lekovi budu besplatni za sve ali ne zivimo jos u takvom svetu.
Zuper wrote:Preduzetnicki duh Henrija Forda lezi u nasem kolegi
Bojim se samo da ce cene svih lekova na kraju da formira 3-4 velike farmaceutske kuce.
zavisi od zemlje do zemlje. u većini Evropskih zemalja se cene lekova dogovaraju između asocijacije proizvođača i države, svake godine ili u periodu od nekoliko godina.
u UK postoji agencija koja odobrava da li lek ulazi ili ne ulazi u sistem NHS. ako je preskup ne ulazi, što znači da neće biti dostupan za 90% tržišta, što je veoma jak argument u rukama vlade kada pregovara o ceni.
Zuper wrote:Preduzetnicki duh Henrija Forda lezi u nasem kolegi
Ne nego postoji mehanizam zahvaljujuci kome ljudi sada, na primer, Sortis placaju oko 2.000 dinara, a za paracetamol istresaju sitninu iz dzepa. Cene u Americi su njihov problem i anomalija koju sami treba da rese, ali to se svakako ne odnosi na eksperimentalni lek sa izuzetno ogranicenom primenom ali sa ogromnim implikacijama za medicinu i farmakopeju.
Drugi deo ne znam kako da razumem, bukvalno nista ne ukazuje na takav trend, u zemljama nekadasnjeg Treceg sveta sada buja genericka farmaceutska industrija.
I ja bih zeleo da lekovi budu besplatni za sve ali ne zivimo jos u takvom svetu.
apsolutno. štaviše, zahvaljujući bumu generičkih lekova u Kini i Indiji, danas recimo skoro pa sve afričke države mogu sebi da priušte sve lekove koji se nalaze na WHO essential medicines list.
patent traje 20 godina, market authorization protection uglavnom 10, što znači da kompanije imaju 10 godina da lek isplate i da zarade.
hehe sto se ne udruzi za pjerom woodmanom, i on je u biznisu sa kamerama i snimajem
GoPro has hired J.P. Morgan Chase to help it seek a potential sale, according to people familiar with the matter. J.P. Morgan helped underwrite GoPro's initial public offering in 2014. No sale is assured, said the people, who asked not to be named because the discussions are private. It's unclear if there is an interested buyer for the company. GoPro CEO Nick Woodman told CNBC's Josh Lipton earlier Monday the company would consider a sale or partnership with another company, though it plans to remain independent.
"If there are opportunities for us to unite with a bigger parent company to scale GoPro even bigger, that is something that we would look at," Woodman said.
Vlasnik Industrije mesa "Matijević" Petar Matijević rekao je za Blic da nije "kralj mesa" već "kralj tuge, muke i problema", jer posle kupovine neke društvene firme skoro uvek ima probleme s radnicima koji štrajkuju jer ne žele da im firma bude prodata privatnom vlasniku.
Podsećamo, firma Matijevićevog sina Bojana je pre dva dana kupila hotel "Slavija luks" za 6,5 miliona evra, a nedavno na nagovor sinova i kupio zgradu "Jugoeksporta" na takođe ekskluzivnoj lokaciji u Kolarčevoj, gde takođe planira da otvori hotel.
eto, iste muke ko i vucic, ovog percepiraju kao govno od gazde, a onog kao zlikovca obicnog. u svakom slucaju podrzavam selidbu te seljacine sa svojim poslovima u bg.
Home
by Kinder Lad Tue Nov 07, 2017 2:32 pm
